Originally formed in 2005 around technology developed in the University of Oklahoma Health Sciences Center by the firm's founders - Drs Pereira and Barnch - Biolytx is a pharmaceutical technology company developing a novel antibiotic peptide for potential use in wound healing and in the treatment of serious hospital-acquired infections. Licensed by Biolytx from Oklahoma University, uses of the technology extent to include those infections resistant to current antibiotics. The underpinning research had shown in laboratory studies that a peptide from the CAP37 protein had the ability to kill antibiotic resistant bacteria. For the past decade, Dr Pereira and her Biolytx team have worked to synthesize the peptide in quantities large enough for use in clinical trials.
